we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks.

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.